Transport of apolipoproteins E and J at the blood-brain barrier: Relevance to Alzheimer's disease;Transport des apolipoproteines E et J a la barriere hemato- encephalique: Relation avec la maladie d'Alzheimer

S.T.P. Pharma Sciences

Volumn 7, Issue 1, 1997, Pages 28-36

  Martel, C L ^a   Ghiso, J ^b   Frangione, B ^b   Zlokovic, B V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid Blood brain barrier; Apolipoprotein E; Apolipoprotein J; Transport

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CLUSTERIN; MEGALIN; TAU PROTEIN;

ACTIVE TRANSPORT; ALZHEIMER DISEASE; ANIMAL TISSUE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN CAPILLARY; BRAIN PERFUSION; ENDOCYTOSIS; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVIEW; SENILE PLAQUE;

EID: 0031544347     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. HAASS C., SCHLOSSMACHER M., HUNG A., VIGO-PELFREY C., MELLON A., OSTASZEWSKI B., LIEBERBURG I., KOO E., SCHENK D., TEPLOW D. and SELKOE D.J. - Amyloid β peptide is produced by cultured cells during normal metabolism. - Nature, 359, 322-326, 1992.
2. SEUBERT P., VIGO-PELFREY C., ESCH F., LEE M., DOVEY H., DAVIS D., SINHA S., SCHLOSSMACHER M., WHALEY J., SWINDLEHURST C., McCORMACK R., WOLFERT R., SELKOE D.J., LIEBERBURG I. and SCHENK D. - Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. - Nature, 359, 325-327, 1992.
3. BUSCIGLIO J., GABUZDA D.H., MATSUDAIRA P. and YANKER B.A. - Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. - Proc. Natl. Acad. Sci. USA, 90, 2092-2096, 1993.
4. VIGO-PELFREY C., LEE D., KEIM P., LIEBERBURG I. and SCHENK D.B. - Characterization of β-amyloid peptide from human cerebrospinal fluid. - J. Neurochem., 61, 1965-1968, 1993.
5. GHISO J., WISNIEWSKI T. and FRANGIONE B. - Unifying features of systemic and cerebral amyloidosis. - Mol. Neurobiol., 8, 49-64, 1994.
6. WISNIEWSKI T., GHISO J. and FRANGIONE B. - Alzheimer's disease and soluble Aβ. - Neurobiol. Aging, 15, 143-152, 1994.
7. KATZMAN R. - Alzheimer's disease. - N. Engl. J. Med., 314, 964-973, 1986.
8. WISNIEWSKI H.M., NARANG H.K. and TERRY R.D. - Neurofibrillary tangles of paired helical filaments. - J. Neurol. Sci., 27, 173-178, 1976.
9. BANKS W.A. and KASTIN A.J. - Passage of peptides across the blood-brain barrier : pathophysiological perspectives. - Life Sci., 59, 1923-1943, 1996.
10. KANNAN R., YI J.R., TANG D., LI Y., ZLOKOVIC B.V. and KAPLOWITZ N. - Evidence for the existence of a sodium dependent glutathione (GSH) transporter. - J. Biol. Chem., 217, 9754-9758, 1996.
11. DAVSON H., ZLOKOVIC B.V., RAKIC L. and SEGAL M.B. - Introduction to the Blood-Brain Barrier. - Macmillan Press, London, 1993, pp. 1-55.
12. PRELLI F., CASTANO E.M., GLENNER G.G. and FRANGIONE B. - Differences between vascular and plaque core amyloid in Alzheimer's disease. - J. Neurochem., 51, 648-651, 1988.
13. MILLER D.L., PAPAYANNOPOULOS I.A., STYLES J., BOBIN S.A., LIN Y.Y., BIEMANN K. and IQBAL K. - Amyloid β-peptide is produced by cultured cells during normal metabolism. - Arch. Biochem. Biophys., 301, 41-52, 1993.
14. TERRY R.D., MASLIAH E. and HANSEN L.A. - Structural basis of the cognitive alterations in Alzheimer disease. - In : Alzheimer Disease, R.D. Terry, R. Katzman and K.I. Bick Eds., Raven Press, Ltd ., New York, 1994, pp. 179-196.
15. AVILA J., LEDESMA M. D., CORREAS I., MEDINA M., BONAY P., COLACO C. and MONTEJO DE GARCINI E. - Association of Tau with paired helical filaments. - In : Research Advances in Alzheimer's Disease and Related Disorders, K. Iqbal, J.A. Mortimer, B. Winblad and H.M. Wisniewski Eds., John Wiley & Sons, Chichester, 1995, pp. 503-512.
16. BEGLEY D.J. - Peptides and the blood-brain barrier : the status of our understanding. - Ann. NY Acad. Sci., 739, 89-100, 1994.
17. ERMISCH A., BRUST P., KRETZSCHMAR R. and RUEHLE H.J. - Peptides and blood-brain barrier transport. - Physiol. Reviews, 72, 489-527, 1993.
18. KOUDINOV A., MATSUBARA E., FRANGIONE B. and GHISO J. - The soluble form of Alzheimer's amyloid β protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. - Biochem. Biophys. Res. Commun., 205, 1164-1171, 1994.
19. MATSUBARA E., FRANGIONE B. and GHISO J. - Characterization of apolipoprotein J-Alzheimer's Aβ interaction. - J. Biol. Chem., 270, 7563-7567, 1995.
20. WISNIEWSKI T. and FRANGIONE B. - Apolipoprotein E : a pathologic chaperone protein in patients with cerebral and systemic amyloid. - Neurosci. Lett., 135, 235-238, 1992.
21. GHISO J., MATSUBARA E., KOUDINOV A., CHOI-MIURA N.H., TOMITA M., WISNIEWSKI T. and FRANGIONE B. - The cerebrospinal fluid soluble form of Alzheimer's amyloid β is complexed to SP40, 40 (Apo J), an inhibitor of the complement membrane attack complex. - Biochem. J., 293, 27-30, 1993.
22. HERZ J. and WILLNOW T.E. - Functions of the LDL receptor gene family. - Ann. NY Acad. Sci., 737, 14-19, 1993.
23. MERESSE S., DELBART C., FRUCHART J.C. and CECCHELLI R. - Low density lipoprotein receptor on endothelium of brain capillaries. - J. Neurochem., 53, 340-345, 1989.
24. RUBINSZTEIN D.C. - Apolipoprotein E : a review of its roles in lipoprotein metabolism, neuronal growth and repair and as a risk factor for Alzheimer's disease. - Psych. Med., 25, 223-229, 1995.
25. SIEST G., PILLOT T., REGIS-BAILLY A., LEININGER-MULLER B., STEINMETZ J., GALTEAU M.-M. and VISVIKIS S. - Apolipoprotein E : an important gene and protein to follow in laboratory medicine. - Clin. Chem., 41, 1068-1086, 1995.
26. LADU M.J., LUKENS J.R., PEDERSON T.M., REARDON C.A. GETZ G.S. and FALDUTO M.T. - Particle size distribution of native apolipoprotein E in the presence of 13-amyloid peptide. - Soc. Neurosci. Abst., 21, 5, 1995.
27. STRITTMATTER W., SAUNDERS A., SCHMECHER D., PERICAK-VANCE M., ENGHILD J., SALVERSEN G. and ROSES A. - Apolipoprotein E : high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. - Proc. Natl. Acad. Sci. USA, 90, 1977-1981, 1993.
28. POLVIKOSKI T., SULKAVA R., HALTIA M., KAINULAINEN K., VUORIO A., VIERKKONIEMI A., NIINISTOE L., HALONEN P. and KONTULA K. - Apolipoprotein E, dementia, and cortical deposition of β amyloid protein. - New Engl. J. Med., 333, 1242-1247, 1995.
29. CASTANO E.M., PRELLI F., GOLABEK R., KUMAR A., SOTO C. and FRANGIONE B. - Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E. - Biochem. J., 306, 599-604, 1995.
30. EVANS K.C., BERGER E.P., CHO C.G., WEIGRABER K.H. and LANSBURY P.T. Jr. - Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation : implications for the pathogenesis and treatment of Alzheimer's disease. - Proc. Natl. Acad. Sci. USA, 92, 763-767, 1995.
31. ZLOKOVIC B.V. - Cerebrovascular permeability to peptides : manipulations of transport systems at the blood-brain barrier. - Pharm. Res., 12, 1395-1406, 1995.
32. ZLOKOVIC B.V., GHISO J., MACKIC J.B., MCCOMB J.G., WEISS M.H. and FRANGIONE B. - Blood-brain barrier transport of circulating Alzheimer's amyloid β. Biochem. Biophys. Res. Commun., 197, 1034-1040, 1993.
33. ZLOKOVIC B.V., MARTEL C.L., MACKIC J.B., MATSUBARA E., WISNIEWSKI T., McCOMB J.G., FRANGIONE B. and GHISO J. - Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid β. - Biochem. Biophys. Res. Commun., 205, 1431-1437, 1994.
34. MARTEL C.L., MACKIC J.B., McCOMB J.G., GHISO J., FRANGIONE B. and ZLOKOVIC B.V. - Blood brain barrier regulation of transport and cerebral capillary sequestration of circulating apolipoproteins E3 and E4 and their complexes with Alzheimer's amyloid β. - submitted.
35. ZLOKOVIC B.V., MARTEL C.L., MATSUBARA E., McCOMB J.G., ZHENG G., McCLUSKEY R.T., FRANGIONE B. and GHISO J. - Glycoprotein 330/megalin : probable role in receptor mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers. - Proc. Natl. Acad. Sci. USA, 93, 2580-2586, 1995.
36. YAN S.D., CHEN X., FU J., CHEN M., ZHU H., ROHER A., SLATTERY T., ZHAO L., NAGASHIMA M., MORSER J., MIGHELI A., NAWROTH P., STER D. and SCHMIDT A.M. - RAGE and amyloid β peptide neurotoxicity in Alzheimer's disease. - Nature, 382, 685-691, 1996.
37. EL KHOURY J., HICKMAN S.E., THOMAS C.A., CAO L., SILVERSTEIN S.C. and LOIKE J.D. - Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. - Nature, 382, 716-719, 1996.
38. KOUNNAS M.Z., LOUKINOVA E.B., STEFANSSON S., HARMONY J.A.K., BREWER B.H., STRICKLAND D.K. and ARGRAVES W.S. - Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. - J. Biol. Chem., 270, 13070-13075, 1995.
39. WILLNOW T.E., GOLDSTEIN J.L., ORTH K., BROWN M.S. and HERZ J. - Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen-activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. - J. Biol. Chem., 267, 26172-26180, 1992.
40. DE SILVA H.V., STUART W.D., DUVIC C.R., WETTERAU J.R., RAY M.J., FERGUSON D.G., ALBERS H.W., SMITH W.R. and HARMONY J.A.K. - A 70 kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. - J. Biol. Chem., 265, 13240-13247, 1990.
41. GOLABECK A., MARQUES M.A., LALOWSKI M. and WISNIEWSKI T. - Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid. - Neurosci. Lett., 191, 79-82.
42. ZLOKOVIC B.V. - Cerebrovascular transport of Alzheimer's amyloid β and apolipoproteins J and E : possible anti-amyloidogenic role of the blood-brain barrier. - Life Sci., 59, 1483-1497, 1996.
43. GLASS C.K., PITTMAN R.C., KELLER G.A. and STEINBERG D. - Tissue sites of degradation of apoprotein A-I in the rat. - J. Biol. Chem., 258, 7161-7167, 1983.
44. MATSUBARA E., SOTO C., GOVERNALE S., FRANGIONE B. and GHISO J. - Apolipoprotein J and Alzheimer's amyloid β solubility. - Biochem. J., 316, 671-679, 1996.
45. MATTSON M.P. and RYDEL R.E. - Amyloidox-tox transducers. - Nature, 382, 674-675, 1996.
46. MAURY C.P.J. - Molecular pathogenesis of β-amyloidosis in Alzheimer's disease and other cerebral amyloidoses. - Lab. Investig., 72, 4-16, 1995.
47. GREGG R.E., GHISELLI G. and BREWER H.B. Jr. - Apolipoprotein E Bethesda : a new variant of apolipoprotein E associated with type III hyperlipoproteinemia. - J. Clin. Endocrinol. Metab., 57, 969-974, 1983.
48. STEINMETZ A., JAKOBS C., MOTZNY S. and KAFFARNIK H. - Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis, 9, 405-411, 1989.
49. WEISGRABER K.H. - Apolipoprotein E distribution among human plasma lipoproteins : role of the cysteine-arginine interchange at residue 112. - J. Lipid Res., 31, 1503-1511, 1990.
50. SEGAL M.B. and ZLOKOVIC B.V. - The Blood-Brain Barrier, Amino Acids and Peptides, Kluwer Academic Publishers, Boston, 1990.
51. BONATE P.L. - Animal models for studying transport across the blood-brain barrier. - J. Neurosci. Meth., 56, 1-15, 1995.
52. STRITTMATTER W.J., SAUNDERS A.M., GOEDERT M., WEISGRABER K.H., DONG L.M., JAKES R., HUANG D.Y., PERICAK-VANCE M., SCHMECHEL D. and ROSES A.D. - Isoform-specific interactions of apolipoprotein E with microtubule associated protein tau : Implications for Alzheimer disease. - Proc. Natl. Acad. Sci. USA, 91, 11183-11186, 1994.
53. ZLOKOVIC B.V., BEGLEY D.J., DURICIC B.M. and MITROVIC D.M. - Measurement of solute transport across the blood-brain barrier in the perfused guinea pig brain, method and application to N-methyl-a-aminoisobutyric acid. - J. Neurochem., 46, 1444-1451, 1986.
54. SHAYO M., McLAY R.N., KASTIN A.J. and BANKS W.A. - The putative blood brain barrier transporter for the β-amyloid binding protein apolipoprotein J is saturated at physiological concentrations. - Life Sci., in press.
55. LINTON M.F., GISH R., HUBL S.T., BUTLER E., ESQUIVEL C., BRY W.I., BOYLES J.K., WARDELL M.R. and YOUNG S.G. - Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. - J. Clin. Invest., 88, 270-281, 1991.